CANbridge Grants Share Options and RSUs Equal to 1.25% of Share Capital

CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has issued an announcement.

CANbridge Pharmaceuticals has granted 6,372,575 share options to 30 grantees and an equal number of restricted share units (RSUs) to 28 grantees under its post-IPO incentive schemes, representing about 1.25% of its issued share capital. The share options, which include awards to directors, service providers and non-connected employees, carry an exercise price of HK$2.32 per share and vest over time and upon meeting specific performance milestones such as license-out deals, commercial sales targets and financing achievements, underscoring the company’s use of equity incentives to drive long-term performance and retain key talent.

The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.

More about CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a biotechnology company listed in Hong Kong that focuses on developing and commercializing therapeutics, operating under a post-IPO equity incentive framework to align employee and management interests with shareholder value.

Average Trading Volume: 1,881,047

Technical Sentiment Signal: Buy

Current Market Cap: HK$1.14B

Find detailed analytics on 1228 stock on TipRanks’ Stock Analysis page.